ENU200

**ENU200** is a repurposed, patent-pending, orally deliverable **small-molecule antiviral** being developed by **Ennaid Therapeutics** for treatment of **asymptomatic, mild to moderate COVID-19**. Public descriptions indicate that it was previously approved by the FDA for a different indication, but the underlying active ingredient and original marketed name have not been publicly disclosed. Ennaid reported that in silico and AI-enabled discovery work identified ENU200 as a candidate with activity against **SARS-CoV-2 spike glycoprotein** and the viral **main protease**, supporting development as an oral, at-home therapy; **Catalent** partnered with Ennaid to develop a **powder-in-capsule** clinical-trial formulation.

Other names

repurposed drug oral COVID-19Ennaid Therapeutics SARS-CoV-2 S glycoprotein protease protein inhibitor